General inquiries: 314-454-6018

Research areaPrinciple investigator(s)Email
Brain tumors (neuro-oncology)Mohamed S. Abdelbaki, MDmohameda@wustl.edu
Cancer predispositionTodd Druley, MD, PhDdruley_t@wustl.edu
 Andrea Stacy, MS, CGCastacy@wustl.edu
Hematological malignancy (leukemia & lymphoma)Jeffrey Magee MD, PhDmageej@wustl.edu
 Laura Schuettpelz MD, PhDschuettpelz_l@wustl.edu
Hemostasis and thrombosis (clotting/bleeding disorders)David Wilson, MD, PhDwilson_d@wustl.edu
Immune disordersJeffrey Bednarski, MD, PhDbednarski_j@wustl.edu
Sickle cell diseaseMonica Hulbert, MDmonicahulbert@wustl.edu
Solid tumorsFrederick Huang, MDhuang_f@wustl.edu
Stem cell transplantation and cellular therapyShalini Shenoy, MDshalinishenoy@wustl.edu
 Sima Bhatt, MDbhatts@wustl.edu
SurvivorshipRobert Hayashi, MDhayashi_r@wustl.edu

Studies

All cancers
Principal investigatorTitle
Robert Hayashi, MDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Brain tumors
Principal investigatorTitle
Neuro/Onc, IDS pharmacySingle-arm, multicenter Phase I/Ib  studyof avelumab + lenvatinib in children with primary CNS tumors
Margaret Shatara, MDPhase 1/2 Study  of  Bempegaldesleukin in Combination with Nivolumab in  Children, Adolescents, and Young Adults with Recurrent or Refractory  Malignancies (PIVOT IO 020)
Mohamed S. Abdelbaki, MDA Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Robert Hayashi, MDSelinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Glioma
Karen Gauvain, MDStudy of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
Karen Gauvain, MDUsing MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Joshua Rubin, MD, PhDA Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults with Previously Untreated Low Grade Glioma
Karen Gauvain, MDPhase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Joshua Rubin, MD, PhDMaintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Karen Gauvain, MDReduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Karen Gauvain, MDCA209-908 – Phase Ib/II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
Karen Gauvain, MDPNOC 001 – Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children
Karen Gauvain, MDH3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
Karen Gauvain, MDPNOC013 – A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Karen Gauvain, MDPhase I-II Study of MEK162 for Children with Ras/Raf Pathway Activated Tumors
Karen Gauvain, MDModified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Karen Gauvain, MDVemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Joshua Rubin, MD, PhDStudy Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Joshua Rubin, MD, PhDCognitive Biomarkers in Pediatric Brain Tumor Patients
Shalini Shenoy, MDANBL1531: Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Karen Gauvain, MDExpanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas
Karen Gauvain, MDREGN2810 in Pediatric Patients with Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed or Recurrent Glioma
Karen Gauvain, MDAn Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type I
Karen Gauvain, MDVeliparib, Radiation Therapy, and Temozolimide in Treating Participants with Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations
Karen Gauvain, MDCabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
Cancer predisposition
Principal InvestigatorTitle
Robert Hayashi, MDPhenotypic Characterizations of Cancer Predisposition Syndromes
Hematologic malignancies
Principal investigatorTitle
Neha Mehta-Shah, MD / Robert Hayashi, MDA Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
Robert Hayashi, MDAAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)
Robert Hayashi, MDResponse-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Robert Hayashi, MDTrentinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Robert Hayashi, MDA Phase II Study of Ruxolitinib with Chemotherapy in Children with Acute Lymphoblastic Leukemia
Robert Hayashi, MDBlinatumomab in Treating Younger Patients with Relapsed B-Cell Acute Lymphoblastic Leukemia
Robert Hayashi, MDCombination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Robert Hayashi, MDA Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Robert Hayashi, MDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Robert Hayashi, MDA Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Robert Hayashi, MDBrentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma
Robert Hayashi, MDA Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma
Robert Hayashi, MDPost Transplant Lymphoproliferative Disease: Analysis of Outcome to Chemotherapy Treatment
Robert Hayashi, MDRituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients with EBV-Positive Cluster of Differentiation (CD) 20-Positive Post-Transplant Lymphoproliferative Disorder
Shalini Shenoy, MDA Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Jeffrey Magee, MDMatched Targeted Therapy for High-Risk Leukemias and MDS
Robert Hayashi, MDA Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years old, with Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
Sickle cell disease
Principal investigatorTitle
Shalini Shenoy, MDA Multi-center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: a Sickle Transplant Alliance for Research (STAR) Project
Allison King, MD, PhDSpecifying Interventions From the Sickle Cell Disease Implementation Consortium
Shalini Shenoy, MD A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease
Solid tumors
Principal investigatorTitle
Amy Armstrong, MDBlood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
Amy Armstrong, MDPhase 1 trial of the LSD1 Inhibitor Seclidenstat (SP-2577) with and without Topotecan and Cyclophosphamide in patients with relasped or refractory Ewing Sarcoma and select Sarcomas
Mohamed S. Abdelbaki, MDA Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Amy Armstrong, MD An Open-Label, Multicenter Phase 1/2 Study of Surufatinib in Combination with Gemcitabine in Pediatric, Adolescent, and Young Adult Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MDA Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Robert Hayashi, MDA Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors
Robert Hayashi, MDA Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Amy Armstrong, MDA Maintenance Protocol of Sirolimus in Combination with Metronomic Chemotherapy in Children with High-Risk Solid Tumors
Frederick Huang, MDA Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Frederick Huang, MD Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Robert Hayashi, MDSelinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High Grade Gliomas
Karen Gauvain, MDStudy of RXDX-101 in Children with Recurrent of Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
Robert Hayashi, MDPI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Robert Hayashi, MDActive Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Frederick Huang, MD Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Todd Druley, MD, PhD International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
Alok Kothari, MDTreating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Alok Kothari, MDErlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Robert Hayashi, MDNivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Robert Hayashi, MDWEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Robert Hayashi, MDA Study of Pembrolizumab (MK-3475) in Pediatric Participants with an Advanced Solid Tumor or Lymphoma
Robert Hayashi, MDPI3K/mTOR Inhibitor LY3023414 in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3k/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDADVL1614 – A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents or Young Adults with Recurrent or Relapsed Solid Tumors
Robert Hayashi, MDPrexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MDNanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MDA Study of Ramucirumab (LY3009806) in Children with Refractory Solid Tumors
Robert Hayashi, MDPevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Robert Hayashi, MDEntinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
Robert Hayashi, MDAccelerated v’s Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumours
Robert Hayashi, MDActive Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Robert Hayashi, MDPazopanib Paediatric Phase II Trial Children’s Oncology Group (COG) in Solid Tumors
Robert Hayashi, MDBiomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Robert Hayashi, MDStudy of Kidney Tumors in Younger Patients
Robert Hayashi, MDAccelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (P3BEP)
Robert Hayashi, MDLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDSelumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDVemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Robert Hayashi, MDPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Stem cell transplant & cellular therapy
Principal investigatorTitle
Sima Bhatt, MDBMT CTN 1904- Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Sima Bhatt, MDReal-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and other Clinical Conditions Treated with Emapalumab across Treatment Centers in the US (REAL-HLH Study)
Shalini Shenoy, MDA Pilot Study in the Treatment of Refractory BK Infections with Related Donor BK Cytotoxic T-Lymphocytes in Children, Adolescent, and Young Adult Recipients
Shalini Shenoy, MDA Pilot Study in the Treatment of Refractory EBV Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescent, and Young Adult Recipients
Peter Westervelt, MD, PhD; Shalini Shenoy, MDClinical Transplant-related Long-term Outcomes of Alternative Donor Allogeneic Transplant (CTRL-ALT-D)
Shalini Shenoy, MDNYMC 579: A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients
Shalini Shenoy, MDA Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents, and Young Adult Recipients – NYMC 580
Shalini Shenoy, MDBone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (STRIDE2) (BMT CTN 1503)
Shalini Shenoy, MDReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Jeffrey Bednarski, MD, PhDCytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant
Shalini Shenoy, MDCampath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Shalini Shenoy, MDUVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Shalini Shenoy, MDAn Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Robert Hayashi, MDPrevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics
Andrew Cluster, MDAnti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (LASCR)
Shalini Shenoy, MDHaploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)
Shalini Shenoy, MDOptimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)
Sima Bhatt, MDCAR-T Cell Therapy for Acute Pre-B Leukemia and Lymphoma
Jeffrey Bednarski, MD, PhDReduced Intensity Transplant for Immune Deficiency Disorders (Immune Disorder HSCT Protocol)
Shalini Shenoy, MDPhase ½ Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Shalini Shenoy, MDA Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease
Survivorship
Principal investigatorTitle
Robert Hayashi, MDLong-Term Follow-Up of Patients Who Have Participated in Children’s Oncology Group Studies
Joshua Rubin, MD, PhDNeuropsychological and Behavioral Testing in Younger Patients With Cancer
Robert Hayashi, MDGenetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Robert Hayashi, MDPrevalence of Ototoxicity following Bone Marrow Transplantation and Stem Cell Transplantation in Pediatrics
Robert Hayashi, MDChildhood Cancer Survivor Study (CCSS) – Expansion
Robert Hayashi, MDKnowledge and perceptions of infertility in adolescent female cancer survivors and parents
Robert Hayashi, MDLate Onset and Asymmetric Sensorineural Hearing Loss in Pediatric Cancer Survivors Following Treatment with Cisplatin Containing Chemotherapy Regimens
Caroline Mohrmann, PNPPatient, Family, and Provider Decision-Making in the Setting of Chemotherapy-Induced Hearing Loss
Robert Hayashi, MDEffects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Miranda CametRetrospective Review of Audiologic Test Results for Pediatric Patients with Beckwith-Wiedemann Syndrome and hemihypertrophy
Shalini Shenoy, MDA Multi-center Retrospective Registry of Children with Sickle Cell Disease following Hematopoietic Cell Transplantation: a Sickle Transplant Alliance for Research (STAR) Project